ArticlePloS one2025
Optimizing the preparation of labeled N-glycans for rapid, simplified, and high-precision analysis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glycan structures hold promise as biomarkers for the early detection of diseases, owing to their sensitive reflection of cellular states. However, glycan analysis remains complex and time-consuming, and the use of hazardous chemicals in traditional hydrazinolysis methods presents a significant barrier to broader application and cross-disciplinary research. To enable efficient glycan biomarker discovery, we aimed to develop a simple and accurate N-glycan analysis method capable of high-throughput sample processing. A key feature of this study is the use of pyridylamination, a fluorescent labeling technique that enables high isomer separation efficiency in reversed-phase LC/MS. After comparing various methods for N-glycan release and purification, we identified Rapid PNGase F (New England Biolabs) and BlotGlyco (Sumitomo Bakelite) as optimal for this application. To improve accuracy by reducing artifact formation, the BlotGlyco protocol was modified from the manufacturer's original instructions. Using this optimized workflow, we successfully analyzed human serum, human urine, and CHO-K1 membrane fractions, demonstrating that distinct glycan structures in each sample type could be effectively separated and quantified. This work supports the broader adoption of glycan analysis across diverse research fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.